Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Reducing hyperlipidaemia and CHD

By Steve Ohlsen and David Rogers

Coronary heart disease (CHD) accounts for 21 per cent of deaths in England and Wales and 24 per cent in Scotland. However, this disease is preventable and one way of reducing risk is to prevent or treat chronic risk factors such as hyperlipidaemia.

Hyperlipidaemia

Two thirds of men and women have blood total cholesterol (TC) levels over 5.0mmol/L. The prevalence of raised cholesterol increases with age. In men, the proportion with cholesterol levels over 5.0mmol/L increases from 23 per cent in those aged between 16 and 24 years to 82 per cent in those aged between 55 and 64. This compares with 27 per cent in women aged between 16 and 24 years and 91 per cent in those aged between 65 and 74.

The higher the TC and “bad” low-density lipoprotein (LDL) cholesterol, the higher the death rate from a heart attack.The higher the level of “good” high-density lipoprotein (HDL) cholesterol, the lower the risk of a heart attack.

Managing hyperlipidaemia in both primary and secondary care requires an understanding of how this condition is often linked to other CHD risk factors. In fact, many of these risk factors, such as hypertension, smoking and diabetes, are interrelated.

Diabetes

Hyperlipidaemias are common in patients with diabetes and further increase the risk of ischaemic heart disease, especially in people with type 2 diabetes. The major abnormalities seen are low HDL cholesterol and high triglyceride (TG) levels. In addition, even if LDL cholesterol concentration is normal or only slightly raised, the LDL particles in people with type 2 diabetes can be more atherogenic than in people without diabetes.

Type 2 diabetes is often linked with older age groups, obesity and hypertension.

Download the attached PDF to read the full article.

Citation: The Pharmaceutical Journal URI: 10997170

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary information

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.